250 related articles for article (PubMed ID: 34551970)
21. In vitro drug response and efflux transporters associated with drug resistance in pediatric high grade glioma and diffuse intrinsic pontine glioma.
Veringa SJ; Biesmans D; van Vuurden DG; Jansen MH; Wedekind LE; Horsman I; Wesseling P; Vandertop WP; Noske DP; Kaspers GJ; Hulleman E
PLoS One; 2013; 8(4):e61512. PubMed ID: 23637844
[TBL] [Abstract][Full Text] [Related]
22. Transcriptional Dependencies in Diffuse Intrinsic Pontine Glioma.
Nagaraja S; Vitanza NA; Woo PJ; Taylor KR; Liu F; Zhang L; Li M; Meng W; Ponnuswami A; Sun W; Ma J; Hulleman E; Swigut T; Wysocka J; Tang Y; Monje M
Cancer Cell; 2017 May; 31(5):635-652.e6. PubMed ID: 28434841
[TBL] [Abstract][Full Text] [Related]
23. Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations.
Buczkowicz P; Hoeman C; Rakopoulos P; Pajovic S; Letourneau L; Dzamba M; Morrison A; Lewis P; Bouffet E; Bartels U; Zuccaro J; Agnihotri S; Ryall S; Barszczyk M; Chornenkyy Y; Bourgey M; Bourque G; Montpetit A; Cordero F; Castelo-Branco P; Mangerel J; Tabori U; Ho KC; Huang A; Taylor KR; Mackay A; Bendel AE; Nazarian J; Fangusaro JR; Karajannis MA; Zagzag D; Foreman NK; Donson A; Hegert JV; Smith A; Chan J; Lafay-Cousin L; Dunn S; Hukin J; Dunham C; Scheinemann K; Michaud J; Zelcer S; Ramsay D; Cain J; Brennan C; Souweidane MM; Jones C; Allis CD; Brudno M; Becher O; Hawkins C
Nat Genet; 2014 May; 46(5):451-6. PubMed ID: 24705254
[TBL] [Abstract][Full Text] [Related]
24. Repurposing the anti-epileptic drug sodium valproate as an adjuvant treatment for diffuse intrinsic pontine glioma.
Killick-Cole CL; Singleton WGB; Bienemann AS; Asby DJ; Wyatt MJ; Boulter LJ; Barua NU; Gill SS
PLoS One; 2017; 12(5):e0176855. PubMed ID: 28542253
[TBL] [Abstract][Full Text] [Related]
25. Signal Transduction in Diffuse Intrinsic Pontine Glioma.
Duchatel RJ; Jackson ER; Alvaro F; Nixon B; Hondermarck H; Dun MD
Proteomics; 2019 Nov; 19(21-22):e1800479. PubMed ID: 31328874
[TBL] [Abstract][Full Text] [Related]
26. MELK Inhibition in Diffuse Intrinsic Pontine Glioma.
Meel MH; de Gooijer MC; Guillén Navarro M; Waranecki P; Breur M; Buil LCM; Wedekind LE; Twisk JWR; Koster J; Hashizume R; Raabe EH; Montero Carcaboso A; Bugiani M; van Tellingen O; van Vuurden DG; Kaspers GJL; Hulleman E
Clin Cancer Res; 2018 Nov; 24(22):5645-5657. PubMed ID: 30061363
[No Abstract] [Full Text] [Related]
27. PI3K/mTOR is a therapeutically targetable genetic dependency in diffuse intrinsic pontine glioma.
Duchatel RJ; Jackson ER; Parackal SG; Kiltschewskij D; Findlay IJ; Mannan A; Staudt DE; Thomas BC; Germon ZP; Laternser S; Kearney PS; Jamaluddin MFB; Douglas AM; Beitaki T; McEwen HP; Persson ML; Hocke EA; Jain V; Aksu M; Manning EE; Murray HC; Verrills NM; Sun CX; Daniel P; Vilain RE; Skerrett-Byrne DA; Nixon B; Hua S; de Bock CE; Colino-Sanguino Y; Valdes-Mora F; Tsoli M; Ziegler DS; Cairns MJ; Raabe EH; Vitanza NA; Hulleman E; Phoenix TN; Koschmann C; Alvaro F; Dayas CV; Tinkle CL; Wheeler H; Whittle JR; Eisenstat DD; Firestein R; Mueller S; Valvi S; Hansford JR; Ashley DM; Gregory SG; Kilburn LB; Nazarian J; Cain JE; Dun MD
J Clin Invest; 2024 Feb; 134(6):. PubMed ID: 38319732
[TBL] [Abstract][Full Text] [Related]
28. Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma.
Taylor KR; Mackay A; Truffaux N; Butterfield Y; Morozova O; Philippe C; Castel D; Grasso CS; Vinci M; Carvalho D; Carcaboso AM; de Torres C; Cruz O; Mora J; Entz-Werle N; Ingram WJ; Monje M; Hargrave D; Bullock AN; Puget S; Yip S; Jones C; Grill J
Nat Genet; 2014 May; 46(5):457-461. PubMed ID: 24705252
[TBL] [Abstract][Full Text] [Related]
29. Children with DIPG and high-grade glioma treated with temozolomide, irinotecan, and bevacizumab: the Seattle Children's Hospital experience.
Crotty EE; Leary SES; Geyer JR; Olson JM; Millard NE; Sato AA; Ermoian RP; Cole BL; Lockwood CM; Paulson VA; Browd SR; Ellenbogen RG; Hauptman JS; Lee A; Ojemann JG; Vitanza NA
J Neurooncol; 2020 Jul; 148(3):607-617. PubMed ID: 32556862
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of mutant PPM1D enhances DNA damage response and growth suppressive effects of ionizing radiation in diffuse intrinsic pontine glioma.
Akamandisa MP; Nie K; Nahta R; Hambardzumyan D; Castellino RC
Neuro Oncol; 2019 Jun; 21(6):786-799. PubMed ID: 30852603
[TBL] [Abstract][Full Text] [Related]
31. ACVR1 Function in Health and Disease.
Valer JA; Sánchez-de-Diego C; Pimenta-Lopes C; Rosa JL; Ventura F
Cells; 2019 Oct; 8(11):. PubMed ID: 31683698
[No Abstract] [Full Text] [Related]
32. Phase 2 study of safety and efficacy of nimotuzumab in pediatric patients with progressive diffuse intrinsic pontine glioma.
Bartels U; Wolff J; Gore L; Dunkel I; Gilheeney S; Allen J; Goldman S; Yalon M; Packer RJ; Korones DN; Smith A; Cohen K; Kuttesch J; Strother D; Baruchel S; Gammon J; Kowalski M; Bouffet E
Neuro Oncol; 2014 Nov; 16(11):1554-9. PubMed ID: 24847085
[TBL] [Abstract][Full Text] [Related]
33. Biopsy in a series of 130 pediatric diffuse intrinsic Pontine gliomas.
Puget S; Beccaria K; Blauwblomme T; Roujeau T; James S; Grill J; Zerah M; Varlet P; Sainte-Rose C
Childs Nerv Syst; 2015 Oct; 31(10):1773-80. PubMed ID: 26351229
[TBL] [Abstract][Full Text] [Related]
34. Pharmacologic inhibition of lysine-specific demethylase 1 as a therapeutic and immune-sensitization strategy in pediatric high-grade glioma.
Bailey CP; Figueroa M; Gangadharan A; Yang Y; Romero MM; Kennis BA; Yadavilli S; Henry V; Collier T; Monje M; Lee DA; Wang L; Nazarian J; Gopalakrishnan V; Zaky W; Becher OJ; Chandra J
Neuro Oncol; 2020 Sep; 22(9):1302-1314. PubMed ID: 32166329
[TBL] [Abstract][Full Text] [Related]
35. Intraarterial delivery of bevacizumab and cetuximab utilizing blood-brain barrier disruption in children with high-grade glioma and diffuse intrinsic pontine glioma: results of a phase I trial.
McCrea HJ; Ivanidze J; O'Connor A; Hersh EH; Boockvar JA; Gobin YP; Knopman J; Greenfield JP
J Neurosurg Pediatr; 2021 Aug; 28(4):371-379. PubMed ID: 34359048
[TBL] [Abstract][Full Text] [Related]
36. Therapeutic targeting of transcriptional elongation in diffuse intrinsic pontine glioma.
Katagi H; Takata N; Aoi Y; Zhang Y; Rendleman EJ; Blyth GT; Eckerdt FD; Tomita Y; Sasaki T; Saratsis AM; Kondo A; Goldman S; Becher OJ; Smith E; Zou L; Shilatifard A; Hashizume R
Neuro Oncol; 2021 Aug; 23(8):1348-1359. PubMed ID: 33471107
[TBL] [Abstract][Full Text] [Related]
37. Magnetic resonance imaging is the preferred method to assess treatment-related skeletal changes in children with brain tumors.
Kaste SC; Kaufman RA; Gajjar A; Broniscer A
Pediatr Blood Cancer; 2013 Sep; 60(9):1552-6. PubMed ID: 23526749
[TBL] [Abstract][Full Text] [Related]
38. The response and survival of children with recurrent diffuse intrinsic pontine glioma based on phase II study of antineoplastons A10 and AS2-1 in patients with brainstem glioma.
Burzynski SR; Janicki TJ; Burzynski GS; Marszalek A
Childs Nerv Syst; 2014 Dec; 30(12):2051-61. PubMed ID: 24718705
[TBL] [Abstract][Full Text] [Related]
39. Developing chemotherapy for diffuse pontine intrinsic gliomas (DIPG).
Gwak HS; Park HJ
Crit Rev Oncol Hematol; 2017 Dec; 120():111-119. PubMed ID: 29198324
[TBL] [Abstract][Full Text] [Related]
40. Potent anti-tumor efficacy of palbociclib in treatment-naïve H3.3K27M-mutant diffuse intrinsic pontine glioma.
Sun Y; Sun Y; Yan K; Li Z; Xu C; Geng Y; Pan C; Chen X; Zhang L; Xi Q
EBioMedicine; 2019 May; 43():171-179. PubMed ID: 31060906
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]